Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Bruce L. Innis, Viravarn Luvira et al.|EClinicalMedicine|2022Cited by 56
Awake Proning as an Adjunctive Therapy for Refractory Hypoxemia in Non-Intubated Patients with COVID-19 Acute Respiratory Failure: Guidance from an International Group of Healthcare WorkersWillemke Stilma, Margaretha C. E. van der Woude, H. de Bruin et al.|American Journal of Tropical Medicine and Hygiene|2021Cited by 39
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Bruce L. Innis, Viravarn Luvira et al.|medRxiv|2021Cited by 8